High dose imatinib (STI571, Gleevec®) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC):: Follow-up of the phase II studies.

被引：0
|
作者：
Talpaz, M
Goldman, JM
Sawyers, CL
Hochhaus, A
Silver, RT
Smith, BD
So, C
Gathmann, I
Druker, BJ
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3369
引用
收藏
页码：905A / 906A
页数：2
相关论文
共 50 条
  • [41] Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients
    Breccia, Massimo
    Latagliata, Roberto
    Molica, Matteo
    Colafigli, Gioia
    Mancini, Marco
    Diverio, Daniela
    Tafuri, Agostino
    Alimena, Giuliana
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) : E95 - E96
  • [42] Long-term follow-up of allogeneic stem cell transplantation (SCT) with reduced intensity conditioning (RIC) for patients (pts) with chronic myeloid leukemia (CML).
    Kebriaei, Partow
    Detry, Michelle
    Carrasco-Yalan, Antonio
    Anagnostopoulos, Athanasios
    Couriel, Daniel
    Khouri, Issa
    Anderlini, Paolo
    Hosing, Chitra
    Alousi, Amin
    Giralt, Sergio
    Champlin, Richard
    de Lima, Marcos
    BLOOD, 2006, 108 (11) : 820A - 821A
  • [43] DASATINIB IS ASSOCIATED WITH DURABLE TREATMENT RESPONSES IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: LONG-TERM FOLLOW-UP FROM THE PHASE I TRIAL (CA180002)
    Cortes, J.
    Sawyers, C. L.
    Kantarjian, H. M.
    Shah, N. P.
    Paquette, R.
    Bleickardt, E.
    Paliwal, P.
    Talpaz, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 47 - 47
  • [44] Imatinib (STI571, Gleevec™) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML):: Results of a randomized phase III study vs interferon-alfa plus cytarabine (IFN plus AraC).
    Larson, RA
    BLOOD, 2002, 100 (11) : 4A - 4A
  • [45] Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy
    Alattar, Mona Lisa
    Cortes, Jorge E.
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Ravandi, Farhad
    Jabbour, Elias
    Shan, Jianqin
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1182 - 1182
  • [46] Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Ravandi, Farhad
    Jabbour, Elias
    Shan, Jianqin
    Cortes, Jorge
    CANCER, 2012, 118 (12) : 3116 - 3122
  • [47] Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Branford, Susan
    Mueller, Martin C.
    Foroni, Letizia
    Druker, Brian J.
    Guilhot, Francois
    Larson, Richard A.
    O'Brien, Stephen G.
    Waltzman, Roger J.
    Mone, Manisha
    Wehrle, Elisabeth
    Radich, Jerald P.
    Goldman, John M.
    BLOOD, 2008, 112 (11) : 129 - 130
  • [48] LONG-TERM SAFETY IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB. SINGLE INSTITUTION ANALYSIS AFTER A MEDIAN FOLLOW-UP OF 9 YEARS
    Breccia, M.
    Molica, M.
    Canichella, M.
    Ranieri, S. Chiatamone
    Massaro, F.
    Colafigli, G.
    Latagliata, R.
    Alimena, G.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 82 - 82
  • [49] LOSS OF PREVIOUS COMPLETE CYTOGENETIC RESPONSE AND ABRUPT BLAST TRANSFORMATION DURING LONG TERM FOLLOW UP OF CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE TREATED WITH IMATINIB
    Bogdanovic, A.
    Milosevic, V.
    Djordjevic, V.
    Lekovic, D.
    Jovanovic, J.
    Fekete, M.
    HAEMATOLOGICA, 2013, 98 : 564 - 564
  • [50] Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study
    Huang, Xiaojun
    Jiang, Qian
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    Wang, Jianxiang
    BLOOD, 2016, 128 (22)
12345